2018 Faculty Members

 

Laleh Amiri-Kordestani, MD

Associate Director and Cardio-oncology Liaison, Division of Oncology Products 1, Office of Hematology Oncology Products, Food and Drug Administration, Center for Drug Evaluation and Research, Silver Spring, MD, USA

founder

Laleh Amiri-Kordestani, M.D. is a clinical team leader and cardio-oncology liaison at the FDA, CDER, Office of Hematology and Oncology Products. At the FDA, Dr. Amiri has focused on cardio-oncology and breast cancer oncology drug development. Dr. Amiri attended the University of Tehran Medical Sciences.  

Conference Topic: Session 11 - Track 2: Incorporating Cardio-Oncology in Clinical Trial Design

Read More...

She did a year of post-doctoral research fellowship in Molecular Genetics Laboratory at NIH and went on to study internal medicine at the Georgetown University/Washington Hospital Center and completed her medical oncology and hematology fellowship at the National Cancer Institute (NCI) in Bethesda, MD. In addition, she pursued an M.S. degree in Clinical Research in the Joint Program of the National Cancer Institute and Duke University. Under the direction of Dr. Sandra Swain, she became familiar with the design and implementation of oncology clinical trials and at the NCI she worked with Dr. Susan Bates focusing on early phase clinical trials. Dr. Amiri remains clinically active, treating breast cancer patients at NCI and practicing inpatient medicine at Georgetown University Hospital.

Saro Armenian, DO, MPH

Associate Professor, Departments of Pediatrics and Population Sciences; Director, Division of Outcomes Research, City of Hope National Medical Centre, Duarte, CA, USA

founder

Dr. Saro Armenian, is an Associate Professor in the Departments of Pediatrics and Population Sciences, and is the Director of the Division of Outcomes Research at City of Hope. He is the immediate past Chair of the Children’s Oncology Group Survivorship and Outcomes Committee, and is a Leukemia & Lymphoma Society Clinical Research Scholar.  

Plenary Lecture: Session 7 - Reconciling Guidelines, Recommendations and Consensus Statements to Provide Optimal Cardio-Oncology Care

Read More...

His own research focuses on understanding the pathophysiology and risk factors for cardiovascular complications such as therapy-related heart failure, coronary artery disease, and stroke in long-term survivors of childhood and adult-onset cancer. Dr. Armenian currently leads a multi-center NIH-funded randomized placebo-controlled clinical trial examining the efficacy and safety of carvedilol for heart failure risk reduction in childhood cancer survivors. In addition, he has a number of ongoing studies evaluating novel strategies for early screening and prevention of cardiovascular disease in cancer survivors, funded by the NIH, the St. Baldrick’s Foundation, American Cancer Society, and the Leukemia and Lymphoma Society.

Greg Armstrong, MD

Pediatric Oncologist, St. Jude Children's Research Hospital, Memphis, TN, USA

founder

Greg Armstrong MD, MSCE is the Principal Investigator of the Childhood Cancer Survivor Study (CCCS).  The CCSS is a multi-institutional, collaborative cohort study initiated in 1994, which has successfully established and followed a cohort of 14,370 five-year survivors of childhood cancer diagnosed between1970-1986 and a population of sibling controls.  

Co-Chair: Session 4 - Cardiovascular Toxicity Prevention and Treatment in Special Populations

Read More...

The cohort, derived through 26 original participating clinical centers, has collected detailed information on cancer diagnosis, therapy received, and outcomes encompassing over 248,000 person-years of follow-up. Under the leadership of Dr. Armstrong and Dr. Melissa Hudson, CCSS Co-PI the CCSS is expanding the cohort to include an additional 10,000 survivors diagnosed between 1987-1999. In addition to maintaining a clinical practice in both pediatric neuro-oncology and pediatric cancer survivor care, Dr. Armstrong, co-chairs the St. Jude Lifetime Cohort (SJLIFE) Cardiopulmonary Working Group and has published many of the early cardiac outcomes within the SJLIFE cohort.  He currently holds an RO1 that is evaluating novel echocardiography endpoints (myocardial strain) for early detection of cardiomyopathy, within the SJLIFE population.

Ana Barac, MD, PhD, FACC

Director, Cardio-Oncology Program; Staff Cardiologist, MedStar Heart and Vascular Institute; Associate Professor of Medicine and Oncology, Georgetown University, Washington, DC, USA

founder

Ana Barac, MD, PhD, is a staff cardiologist at MedStar Heart and Vascular Institute and an Associate Professor of Medicine and Oncology at Georgetown University. Her clinical and research interests focus on the mechanisms, diagnosis and treatment of cardiovascular disease in patients undergoing cancer treatment and she leads MedStar’s Cardio-Oncology program.   

Conference Topic: Session 11 - Track 2: Year in Review - Top Clinical Research Studies in Cardio-Oncology

Read More...

Dr. Barac’ clinical expertise is in cardiac magnetic resonance and echocardiography. She previously was a research fellow at the National Institutes of Health and was a recipient of KL2 Scholar Award from the Georgetown-Howard Universities Center for Clinical and Translational Science for investigations of cardiovascular toxicity in patients with breast cancer. Dr. Barac is the current Chair of the American College of Cardiology (ACC) Cardio-Oncology Council and serves on the editorial boards of the Journal of the American College of Cardiology (JACC), Journal of Cardiovascular Translational Research and the Cardio-Oncology journal.

Anne Blaes, MD, MS

Associate Professor, Division of Hematology, Oncology and Transplantation, Program Director, Adult Cancer Survivor Program, University of Minnesota, Minneapolis, MN, USA

founder

Dr. Anne Blaes is an associate professor in the Division of Hematology, Oncology and Transplantation at the University of Minnesota and a member of the Masonic Cancer Center. She is a graduate from the University of Notre Dame and Loyola University Chicago, Stritch School of Medicine. 

Judge: Session 6 - Young Investigator Competition

Read More...

She completed her residency, chief residency and fellowship, and a masters in clinical research at the University of Minnesota prior to joining the faculty where she has received numerous teaching awards including The Gold Foundation Humanism and Excellence in Teaching Award, an Educational Excellence Award, and an Outstanding Clinical Educator awards. She now directs the Adult Cancer Survivor Program at the University of Minnesota. Dr. Blaes has a special interest in cancer survivorship, the late effects of cancer therapy, and medical education. Her research interests, funded by a BIRCWH K12 award, include quality of life, cardiac complications of chemotherapy, and the late effects of cancer therapy in cancer survivors, particularly breast and colorectal cancer survivors. She is a member of the Alliance for Cancer Clinical Trials Health Outcomes committee and the American Society of Cinical Oncology’s Cancer Survivorship Committee.

Christine Brezden-Masley, MD, PhD, FRCPC

Associate Professor of Medicine, University of Toronto; Head, Division of Hematology/Oncology, St. Michael's Hospital, Toronto, ON, Canada. President, Canadian Cardiac Oncology Network

founder

Dr. Christine Brezden-Masley is a practicing Medical Oncologist and the Division Head of Hematology / Oncology at St. Michael’s Hospital in Toronto. She is the Co-Director of the Hematology/Oncology Clinical Research Group there. She obtained her PhD in Medical Biophysics at Princess Margaret Hospital in Toronto and her Medical Degree from the University of Toronto. She is currently an Associate Professor at the University of Toronto and an Associate Scientist at the Li Ka Shing Knowledge Institute.   

Moderator: Session 10 - Keynote Debate: Are We Too Focused on the QT Interval with Oncology Treatments?

Read More...

She is the founder of the COMET (Community Oncologists of Metropolitan Toronto) Clinical Trials Consortium, a web-based virtual network promoting cancer clinical trials throughout the Toronto Region. She treats both Breast and GI (colorectal and gastric cancers) malignancies and these are the major areas of her clinical research. Her main area of clinical research is cardiotoxicity from cancer therapy and has been the Co-Chair of the Annual Canadian Cardio-Oncology Network meeting, a collaborative national meeting improving cardiac heath in cancer patients. She is currently the President of the Canadian Cardio-Oncology Network. She is active in research, education and has been instrumental in the clinical development of the cancer program at St. Michael’s Hospital.

Daniela Cardinale, MD, PhD

Cardioncology Unit Director, European Institute of Oncology, Milan, Italy

founder

Dr. Daniela Cardinale graduated from the University of Milan in 1987 and specialized in Cardiology (Milan 1992). She holds a PhD in Cardiovascular Physiopathology from the same University (2009). She is currently Director of the Cardioncology Unit of the European Institute of Oncology in Milan, where she has been working since 1994.  

Thomas Force Leadership in Cardio-Oncology Lecture

Co-Chair: Session 11 - Track 2: Cardio-Oncology Research and Investigation

 

Read More...

She has previously worked at the Operative Unit of Intensive Cardiac Care of the Centro Cardiologico Monzino (1987-1990) and at the Cardiology Division of S. Raffaele Hospital of Milan (1990-1994). Her professional experience and investigational interests focus on prevention, early detection, monitoring and treatment of cardiotoxicity; screening of cardiotoxicity in patients with cardiac disease; malignant pericardial effusion evaluation and intrapericardial treatment. Since 2009, she is the Vice-President of the ICOS (International CardiOncology Society). She is a fellow of the European Society of Cardiology.

Joseph Carver, MD

Bernard Fishman Clinical Professor of Medicine; Chief Operating Officer, Abramson Family Cancer Research Institute; Chief of Staff, Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA, USA

founder

Dr. Joseph Carver is the Bernard Fishman Clinical Professor of Medicine at the Abramson Cancer Center of the University of Pennsylvania, the Chief Operating Officer of the Abramson Family Cancer Research Institute of the Abramson Cancer Center of the University of Pennsylvania and the Chief of Staff of the Abramson Cancer Center. His clinical practice is in the subspecialty of Cardio-oncology.  

Co-Chair: Session 12 - How to Develop A Complete Cardio-Oncology Service

Read More...

He was the recipient of the IS Ravdin Master Clinician Award at Penn in 2012. He is one of the Founding Editors of Cardio-oncology Journal. 

Richard A. Chazal, MD, MACC, FACP, FASE

Past President, American College of Cardiology; Medical Director, Heart and Vascular Institute, Lee Health, Fort Myers, FL, USA

founder

Rick Chazal is a senior cardiologist and the Medical Director of the Heart and Vascular Institute for Lee Health, a four hospital, not-for-profit system in Fort Myers, Florida. Dr. Chazal is the Past President of the American College of Cardiology.   He has practiced clinical cardiology in Fort Myers since 1983 with expertise in echocardiography, diagnostic catheterization and coronary computerized tomography angiography.   

Conference Topic: Session 12 - Developing a Cardio-Oncology Program in the Community

Read More...

During his tenure, he has been a participant in multiple clinical trials. Chazal received his undergraduate degree from the University of Florida and went on to complete medical school and Internal Medicine training at the University of South Florida.  Subsequently, Chazal completed a fellowship in Cardiovascular Disease at the Krannert Institute of Cardiology at Indiana University, where he spent one year working under Harvey Feigenbaum, MD, FACC as a designated echocardiography fellow. Chazal served as councillor, treasurer and president of the ACC’s Florida Chapter. Subsequent to his stint as president and governor for the Florida Chapter, he was elected Chair of the ACC Board of Governors.  He has also been ACC Treasurer and Chair of the Budget and Finance Committee. In combined capacities, Chazal has spent thirteen years on the ACC Board of Trustees.  Nationally, Chazal has served as a member and/or chair of over 50 committees and workgroups for the College. He is a member of Alpha Omega Alpha and Omicron Delta Kappa honoraries through the University of South Florida.  He is the recipient of multiple awards from the ACC Florida Chapter, including the Special Achievement Award, the Presidential Citation, the Distinguished Service Award, and the Founder’s Award. In 2011, the Southwest Florida Affiliate of the American Heart Association awarded him their Golden Heart Award, and in 2014 he was designated Distinguished Fellow of the American College of Cardiology. He received the inaugural Community Teaching Award from the Family Medicine Residency Program via Florida State University School of Medicine Fort Myers Program in 2015. The Lee County Medical Society honored Chazal with the Lifetime Achievement Award in 2017. He serves as courtesy assistant professor of medicine for the University of Florida and clinical associate professor of medicine for Florida State University.

Alain Cohen-Solal, MD, PhD

Professor of Cardiology, Faculty of Medicine (Paris 7); Head, Department of Cardiology and Cardiac Rehabilitation, Hospital Lariboisière, Paris, France

founder

Alain Cohen-Solal is Professor of Cardiology at the Faculty of Medicine (Paris 7) and Head of the Department of Cardiology and Cardiac Rehabilitation at the Hospital Lariboisière in Paris, France. He also heads a National Institute of Health and Medical Research Unit (U942) about Biomarkers in cardiology. Professor Cohen-Solal’s research is focused on the care of patients with acute and chronic heart failure. 

Co-Chair: Session 7 - Plenary Lecture: Reconciling Guidelines, Recommendations and Consensus Statements to Provide Optimal Cardio-Oncology Care

Read More...

He runs a multidisciplinary ambulatory program of care of patients with CHF is ongoing as well as a program of cardiac rehabilitation for patients with HF before and after heart transplantation. He has focused his research on several aspects of HF, mainly: the abnormalities of the cardiac and peripheral responses to exercise in CHF, the evaluation of CHF by cardio pulmonary exercise testing, the diagnosis and prognosis role of neuro-hormones and biomarkers, the pathophysiology of diastolic heart failure and oncocardiology. Alain Cohen-Solal is a member of several professional organizations, including the French Society of Cardiology, and the European Society of Cardiology. He has been member of the Working Group on “Heart Failure” (ESC) and Secretary of the European Association of Cardiac Prevention and Rehabilitation of the ESC, Vice President of the Working Group on “Cardiac Rehabilitation and Exercise Physiology” (ESC), President of the Working Group on “Cardiovascular Research” (SFC), EMEA Expert (2003-2004), and Expert at the French Drug Agency (2000-2004). He has also been member of the Heart Failure Guidelines Writing Committee of the ESC in 2008. He is also on the board of the GERS, the WG on Exercise and Rehab of the French Society of Cardiology. He is member of the CardioOncology WG of the ESC since 2017 and leads the CardioOncology Council of the French Society of Cardiology since 2017. Professor Cohen-Solal is author and co-author of over 600 articles published in peer-reviewed medical journals, including Circulation, Journal of the American College of Cardiology, American Journal of Cardiology, Heart, European Heart Journal of Hypertension. He is also member of the Editorial Board of the European Journal of Cardiac Prevention and Rehabilitation. He has been in charge of cardiology research acted as the national coordinator in France on several trials in heart failure, including VICTORIA, ATOMIC-HF, RELAX-AHF2, TRUE-HF, EFFECT-HF, REACH 1, CHARM, SENIORS, SURVIVE, RED-HF, IMPROVEMENT, and SHAPE.

Chau Dang, MD

Chief, Westchester Medical Oncology Service

founder

Dr. Chau Dang is a board-certified medical oncologist and works as part of a multidisciplinary team to care for patients with breast cancer. In her clinical research, she focusses on developing more-effective and less-toxic treatment strategies for women with this disease. Her particular interest is in evaluating combination therapies that include anti-HER2 drugs with chemotherapy in the treatment of patients with early-stage (neoadjuvant and adjuvant) and metastatic HER2-positive breast cancer.

Co-Chair: Session 6 - Young Investigators Competition

Read More...

Dr. Dang’s research has changed standard practice. For example, the widespread use and National Comprehensive Cancer Network (NCCN) endorsement of a dose-dense, anthracycline/taxane-containing chemotherapy regimen followed by trastuzumab in patients with early stage HER2-positive breast cancer was a direct consequence of an investigator-initiated trial led by Dr. Dang at Memorial Sloan Kettering. Additionally, Dr. Dang led another investigator-initiated study that evaluated dual anti-HER therapy with trastuzumab and pertuzumab and chemotherapy for patients with HER2-positive metastatic breast cancer. This led to the NCCN endorsement of this regimen as a standard option in treating patients with metastatic HER2-positive breast cancer. A third investigator-initiated study on dual anti-HER2 therapy with trastuzumab and lapatinib with chemotherapy also had an impact on research worldwide. Dr. Dang is currently leading other research trials, both locally and internationally. From these studies and others, she has also focused on the unique cardiac toxicities of anthracyclines and anti-HER2 agents. To allow for improved patient selection and monitoring, Dr. Dang is collaborating with colleagues from the Cardiology Service with the goal to facilitate early interventions to minimize acute and late cardiac effects of cancer treatment. Dr. Dang also collaborates with exercise scientists and physiologists to conduct research in evaluating the role of exercise as an intervention as part of treatment and follow up care in patients with breast cancer.

Margot Davis, MD SM FRCPC

Clinical Assistant Professor, UBC Cardiology Director, UBC Cardiology-Oncology Program

founder

Margot Davis is a cardiologist at Vancouver General Hospital and St. Paul’s Hospital, a Clinical Assistant Professor at the University of British Columbia, and Director of the UBC Cardiology-Oncology Program. She attended medical school and completed her Internal Medicine residency and Cardiology fellowship at the University of British Columbia. She then completed fellowships in Advanced Heart Failure & Transplant Cardiology and Cardio-Oncology & Cardiac Amyloidosis at Stanford University School of Medicine. She obtained her Master of Science degree in clinical epidemiology at the Harvard School of Public Health.  

Moderator: Session 5 - Keynote Debate: Should Direct Oral Anticoagulants Be Utilized in Cancer Patients to Prevent Thrombosis?

Read More...

Her research interests are focused on the prevention, diagnosis, and management of heart disease related to cancer therapy, cardiac amyloidosis, and advanced heart failure.

Susan Dent, MD, FRCPC

Professor of Medicine, Associate Director of Breast Cancer Research and Co-Director of Cardio-Oncology, Duke University, Durham, NC, USA; Founder & Past-President, Canadian Cardiac Oncology Network

founder

Dr. Susan Dent is a Professor of Medicine, Associate Director of Breast Cancer Research and Co-Director of Cardio-Oncology at Duke University.  She obtained her MD at McMaster University and completed her postgraduate training in Internal Medicine at the University of Ottawa. She continued her training in Medical Oncology in Ottawa, followed by a fellowship year in Clinical Research with the Canadian Cancer Trials Group.   

Plenary Lecture: Session 1 - Cardio-Oncology Historical Perspective: Past, Present and Future

Read More...

Her areas of research interest include breast cancer, and treatment related toxicities with a particular interest in cardiotoxicity. She is the Founder and past-president of the Cardiac Oncology Network, an organization dedicated to improving our understanding of how cancer treatments impact cardiovascular health with the ultimate goal of preventing cardiotoxicity.

Jean-Bernard Durand, MD

Associate Professor, Department of Cardiology, The University of Texas MD Anderson Cancer Centre, Houston, TX, USA

founder

Dr. Durand is the Medical Director of Cardiomyopathy Services, Director of Cardiovascular Genetics Research, and the Director of the Cardiology Fellowship Program at the University of Texas MD Anderson Cancer Centre, in Houston, TX. He is also a Clinical Assistant Professor of Medicine at the Baylor College of Medicine, Staff Physician of the Heart Failure/Heart Failure Transplant Service at St. Luke’s Episcopal Hospital, and the Founder of the worlds first heart failure program dedicated to cardiotoxicity and cancer.  

Co-Chair: Session 1 - Opening Plenary Lecture and Patient Perspective

Read More...

His major research is dedicated to understanding the molecular genetics of cardiomyopathies, primarily the identification of genes responsible for cardiomyopathy of all etiologies. His work also focuses on defining the molecular mechanisms involved in chemotherapy-induced cardiomyopathy. Limited studies have been conducted to define the genetic basis of why patients undergoing cancer treatment develop heart failure and respond to standard medical therapy for treatment of heart failure. Dr. Durand has established the worlds largest database of DNA from patients with heart failure secondary to chemotherapy and have future plans to perform genotyping to identify heart failure susceptibility genes which may predispose patients to development of left ventricular dysfunction and potentially response and recovery of cardiac function. To this date they now have over 600 samples and have plans on obtaining 3000 samples. In addition, he has also developed a tissue bank for further expression studies to identify critical pathways which are common to cancer biology and cardiovascular biology. Dr. Durand's areas of scientific interests also includes genotyping single nucleotide polymorphisms of Tyrosine Kinase Inhibitor-related cardiomyopathy, and acute coronary syndromes in cancer patients with Thrombocytopenia.

Martine Extermann, MD, PhD

Professor of Oncology and Medicine, University of South Florida; Program Leader, Senior Adult Oncology Program, Moffitt Cancer Center and Research Institute, Tampa, FL, USA

founder

Dr. Martine Extermann is Professor of Oncology and Medicine at the University of South Florida. She is the Program Leader of the Senior Adult Oncology Program at the Moffitt Cancer Center. She earned her medical diploma and her medical PhD at the University of Geneva, Switzerland. She has a Swiss Board Certification in Internal Medicine, specialty Oncology-Hematology. She also holds ABIM certifications in Internal Medicine and Medical Oncology.   

Conference Topic: Session 4 - Cardiovascular Considerations in the Geriatric Patient with Cancer

Read More...

She has worked at Moffitt since 1994 and has been a faculty member since 1997. Her research focuses on cancer in the elderly. Her main areas of investigation are comorbidity, comprehensive assessment, and prediction/prevention of treatment toxicity in older cancer patients. She served as Chair of the Eastern Cooperative Oncology Group’s Subcommittee on Aging and is presently involved in the South West Oncology Group. She also served as President of the International Society of Geriatric Oncology (SIOG), of which she is also a founding board member. She served or is serving on several ASCO committees, and on the Editorial Board of the Journal of Clinical Oncology. Dr. Extermann was presented at ASCO 2009 with the B.J. Kennedy Award for Scientific Excellence in Geriatric Oncology. In October 2014 the International Society of Geriatric Oncology (SIOG) presented Dr. Extermann with the Paul Calabresi Award. On October 10, 2015, Dr. Extermann was presented with a Lifetime Achievement Award in Geriatric Oncology by the German Society of Geriatrics and German Society of Hematology/Oncology in Basel, Switzerland.

Anecita P. Fadol, PhD, RN, FNP-BC, FAANP

Associate Professor, Department of Nursing, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

founder

Anecita P. Fadol, PhD is an Associate Professor in the Department of Nursing with a joint appointment in the department of Cardiology at the University of Texas MD Anderson Cancer Center, Houston, Texas, USA. She is also the Education Director of the Nursing Cardiology Program and coordinator of the interdisciplinary “Heart Success Program” for the management of heart failure in patients with cancer. She was inducted as a fellow of the American Association of Nurse Practitioners.

Conference Topic: Session 12 - The Role of Nursing in Cardio-Oncology

Michael G. Fradley, MD

GCOS 2018 Co-Chair; Associate Professor of Medicine, University of South Florida; Cardiologist and Director, Cardio-Oncology Program, Moffitt Cancer Center and Research Institute, Tampa, FL, USA, Moffitt Cancer Center and Research Institute, Tampa, FL, USA

founder

Dr. Fradley is an Associate Professor of Medicine at the University of South Florida with a joint appointment at Moffitt Cancer Cente. He is the director of the combined Moffitt Cancer Center-University of South Florida Cardio-Oncology program. He earned his B.S at Yale University and his MD degree at the Johns Hopkins University School of Medicine.   

Conference Topic: GCOS 2018 Welcome & Introduction

Conference Topic: Opening Remarks and Day 1 Overview

Keynote Debate: Session 10 - Are We Too Focused on the QT Interval with Oncology Treatments? Position: Yes

Read More...

He remained at Johns Hopkins for internal medicine residency and then went on to complete fellowships in both cardiology and clinical cardiac electrophysiology at Massachusetts General Hospital. His research focuses on all aspects of cardio-oncology, however as a trained electrophysioloigst, Dr. Fradley has particular interest in the diagnosis and management of arrhythmic complications associated with traditional and novel cancer therapies. He has co-authored numerous articles in the field of cardio-oncology. He is also actively involved in undergraduate and graduate medical education mentoring medical students, residents and fellows. He developed and serves as the program director for cardio-oncology fellowship at the University of South Florida and Moffitt Cancer Center. He is the co-director of the biomedical research tract in the Scholarly Concentrations Program at the University of South Florida, Morsani College of Medicine. He is also the medical director for the Harvey Simulation Elective and teaches the cardiovascular pathophysiology course for the second year medical students.

John Groarke, MBBCh, MSc, MPH, MRCPI

Associate Physician, Division of Cardiovascular Medicine, Brigham and Women's Hospital; Cardio-Oncologist, Dana Farber Cancer Institute, Instructor of Medicine, Harvard Medical School, Boston, MA, USA

founder

Having graduated with honors and academic awards from medical school at Trinity College Dublin, Ireland, Dr. Groarke completed internal medicine residency and general cardiology fellowship, receiving a Certificate of Completion of Specialist Training from the Royal College of Physicians of Ireland. He then completed clinical fellowships in advanced cardiovascular imaging, cardio-oncology, and advanced heart failure/mechanical circulatory support/heart transplantation at Brigham & Women’s Hospital, Boston between 2011 and 2015.

Co-Chair: Session 2 - New and Emerging Issues in Cardiotoxicity

Read More...

In July 2015, he was appointed as an associate physician with the Division of Cardiovascular Medicine, BWH and Cardio-Oncology Program at Dana Farber Cancer Institute, and as an Instructor of Medicine at Harvard Medical School. In this role, he offers subspecialty expertise in advanced heart failure, mechanical circulatory support, heart transplantation, cardio-oncology, and cardiopulmonary exercise testing. Dr. Groarke has completed a Masters in Science through Trinity College Dublin, and a Masters in Public Health through Harvard School of Public Health. He represents Harvard University on a national expert clinical research committee called the Heart Failure Apprentice Network (HFAN) – a clinical research initiative funded by the National Heart Lung and Blood Institute. His primary clinical research focus is in the field of cardio-oncology, a dynamic and evolving cardiology subspecialty committed to improving the cardiovascular wellbeing of the growing population of cancer survivors. He has secured institutional and industry funding to develop cardio-oncology clinical research across BWH and DFCI. He has made meaningful contributions to cardio-oncology clinical research literature, and is regularly invited to speak at national and international conferences.

Ludhmila Abrahão Hajjar, MD, PhD

Director, Cancer ICU and Division of Cardio-oncology, Cancer Institute, University of São Paulo (USP). Associate Professor, Department of Cardiopneumology, Instituto do Coração (InCor), Hospital das Clínicas, USP. Director, InCor, USP. Director, Cardiology ICU and Heart Failure Unit. Director, Surgical ICU, InCor-USP, São Paulo, Brazil.

founder

Dr Ludhmila Abrahão Hajjar is Associate Professor of Division of Cardiopneumology at the University of São Paulo (USP). She earned her medical diploma at University of Brasília (UNB) and her medical PhD at the University of São Paulo, Brazil. She has a Specialist Certification in Internal Medicine, Cardiology, Intensive Care Medicine and Emergency Medicine. Her research is focused on Cardioncology, Critical Cardiology, Intensive Care Medicine. 

Conference Topic: Session 12 - Cardio-Oncology Programs: An International Perspective

Eric Harrison, MD

Chief of Medicine, HCA Memorial Hospital, CEO PrivaCors Inc Cardio-Orthopaedics, Professor of Medicine, University of South Florida Morsani School of Medicine, Tampa, Florida, USA

founder

Dr. Harrison is the chief of medicine at HCA Memorial Hospital in Tampa Florida and a professor of medicine at the University of South Florida Morsani College of Medicine. Dr. Harrison’s medical career can be divided into 5 multiyear parts.  

Moderator: Session 11 - Track 1: Techniques in Imaging Workshop

Read More...

(1) Education and training culminating in being the first USF cardiac fellow to complete training with the privilege of being named the director of the cath lab at the Tampa VA Hospital while still a fellow but independently funded by the Florida Heart Association. As a fellow, Dr. Harrison received the key to the city of Tampa by the mayor for being a Founder of the Tampa Fire Rescue Program. (2) Hospital based Academic Career at Tampa General Hospital where he was the Associate Director and then Co-director of the Cardiology Center and a Founder of the University of South Florida Medical School and Hillsborough County EMS service. (3) Private Practice Group and Joint Venture This period of his professional life was the creation of a 11 man multihospital physician’s group and founding an outpatient diagnostic heart center as a Co-General partner with a Hospital and with physician limited partners. (4) Corporate Medical Director experience as a national medical director of cardiology, education and research for a 19 acute care hospital network. Creation of a free standing Advanced Cardiac Imaging Center and training program for cardiac PET/CT, CCTA, and cardiac MRI in Tampa, Fl. (5) Sherlock Plaque Analysis Program / AI Curating a CCTA 5,000 case data base and creation of the Sherlock Program for predicting cardiac prognosis based on plaque morphology, composition, and function to predict cardiac events. Startup company PrivaCors to develop this concept nationally with artificial intelligence. PrivaCors has been chosen by IBM Watson Healthcare to join their 24company collaborative to implement AI in medical imaging. Co-founded Cardio-Oncology and founded Cardio-Orthopaedics , a new subspecialty of cardiology to contain the cardiac risk of orthopedic TJA surgery.

Joerg Herrmann, MD

Associate Professor of Medicine; Director, Cardio-Oncology Clinic; Research Director, Ischemic Heart Disease Program , Mayo Clinic College of Medicine, Rochester, MN, USA

founder

Dr. Joerg Herrmann completed his medical school curriculum at the Ruhr University in Bochum, Germany with a doctoral thesis on EGF receptor expression in gynecological malignancies. Thereafter, he worked in the Department of Internal Medicine and Cardiology at the University Clinic Essen until his post-doctoral research fellowship at the Mayo Clinic Rochester in 2000.   

Co-Chair: Session 12 - How To Develop A Complete Cardio-Oncology Service

Read More...

Studies on the ubiquitin-proteasome system in atherosclerosis and use of proteasome inhibitors eventually led to the interest in the cardiovascular side effects of cancer therapeutics. At the Mayo Clinic in Rochester, following completion of residency in internal medicine and fellowship in cardiovascular diseases and interventional cardiology, he joined the Department of Cardiovascular Diseases in 2011. He currently is an Associate Professor of Medicine at the Mayo Clinic College of Medicine and serves as the director of the Cardio-Oncology Clinic and the research director of the Ischemic Heart Disease program. His research interests focus on all aspects of cardio-oncology and the pathophysiology, diagnosis, and treatment of atherosclerosis. He holds an NIH-K08 grant on the pathophysiological role of the immunoproteasome in atherosclerosis. He has published over 100 articles in peer-reviewed journals including the New England Journal of Medicine and Nature Reviews. He serves as a reviewer for over 30 peer-review journals, as well as the NIH, the Dutch Heart Foundation, the Dutch Cancer society, and the British cancer society. He is also a contributor to Braunwald’s Heart Disease, the associated editor of Trends in Cardiovascular Medicine and PracticeUpdate Cardiology, and is the editor of the just recently published textbook Clinical Cardio-Oncology.

W. Gregory Hundley, MD

Director, Pauley Heart Center, Professor of Medicine, Virginia Commonwealth University School of Medicine, Richmond, Virginia, USA

founder

W. Gregory Hundley, MD is currently a Professor of Internal Medicine and the Director of the Pauley Heart Center at Virginia Commonwealth University School of Medicine. Over the past 25 years, he has been utilizing magnetic resonance imaging and other imaging technologies to study the etiology and early evolution of cardiovascular injury, exercise intolerance and heart failure after chemotherapy. 

Conference Topic: Session 8 - Cardiac Tumors: Clinical and Imaging Evaluation of Benign and Malignant Lesions

Read More...

He has accomplished these through a continuous series of NIH grant awards and large, population-based studies. Specifically, three of his grants have focused on the development of cardiovascular injury after chemotherapy, allowing his team to develop additional expertise in assessing both cardiac and vascular dysfunction measures and exercise capacity in women treated for breast cancer who are at risk for cardiovascular injury. He has over 200 peer-reviewed articles that focus on research in this area, and serves as the lead author on the consensus statement of the American Heart Association, American College of Cardiology and American College of Radiology regarding the use of magnetic resonance imaging to study patients with cardiovascular disease. He also serves as Associate Editor for the journal, Circulation and Cardiology Today.

Zaza Iakobishvili, MD, PhD

Director of the Community Cardiology Department in Tel Aviv-Jaffa District of Clalit Health Services, Sackler Faculty of Medicine, University of Tel Aviv, Tel Aviv, Israel

founder

Zaza Iakobishvili, MD, PhD, is the director of the Community Cardiology Department in Tel Aviv-Jaffa district of Clalit Health Services (largest healthcare provider in Israel), since January 2018. Being an academic intensive care cardiologist for most of his career, he took on this position in firm belief that building timely, high quality preventive cardiology services and evidence-based care in the community settings, in close cooperation with hospital-based advanced care systems, will have the largest impact on the patients, as well as the goals of the healthcare systems.  

Co-Chair: Session 1 - Opening Plenary Lecture and Patient Perspective

Read More...

Dr. Iakobishvili received his medical degree in 1988 from the Tbilisi State Medical University and completed his postdoctoral training in Tbilisi Institute of Human Physiology. In 1996 he moved to Israel, completed a 2-year residency in Internal medicine and received Board certification in Internal medicine after successful completing the qualifying exams. He applied to a cardiology fellowship in the Department of Cardiology, Rabin Medical Center and successfully passed Board certification exams in cardiology in 2001. He worked as attending physician in the cardiac intensive care unit between the years 2002 to 2009, when he was appointed to lead the Emergency Cardiology Services. In 2008, Dr. Iakobishvili was appointed the secretary of National Cardiology Board exams committee, for a two-year term. Since 2009, he is the secretary general of the Biennial International Meeting on Acute Cardiac Care, a high-impact meeting with world-wide attendance, endorsed by the ESC and ACCA. In 2011, and again in 2013, he was elected secretary of Israel Heart Society Working Group on Acute Cardiac Care. In 2015, he was elected chairman of this working group. In 2017, he was re-elected for another two-year term. Dr. Iakobishvili is actively engaged in teaching at the Sackler Faculty of Medicine at the University of Tel-Aviv, repeatedly named among “Best Teachers” list of the faculty. He is actively involved in scientific research, and is author/co-author of more than 80 papers and book chapters, published in peer-reviewed journals in the field of cardiology, such as Am Heart J, Am J Cardiol, Int J Cardiol, etc. He is the author of chapters on cardiogenic shock in ESC Textbook on Acute Cardiac Care (2010), Medical Clinics of North of America, AHA book on cardiogenic shock (2011). He presented on international medical meetings as an invited faculty of the ESC in 2007, ESC Acute Cardiac Care meeting in Copenhagen, 2010, Madrid, 2013, Vienna, 2015. In 2015 he presented on the Joint Israel-France association of cardiology meeting “Biomarkers of Cardiotoxicity”. At the annual conference of Israel Heart Society in 2017, he delivered the plenary lecture on cardio-oncology. He takes active participation in the European Society of Cardiology Acute Cardiac Care Association working group on the quality of acute care. Dr. Iakobishvili leads the Acute Coronary Syndrome Israeli Registry (ACSIS). In 2016 ACSIS was enriched by patient-level follow-up data from health management organizations database, thus allowing for the first time to follow the individual patient from the onset of the ACS until the chronic phase and outpatient management. ACSIS 2018 project enrolled about 2,000 new ACS patients and they are closely followed in the outpatient setting. Dr. Iakobishvili has established the first dedicated cardio-oncology clinic in Israel in the Rabin Medical Center in 2013. He is an active participant and invited lecturer on the international cardio-oncology meetings. Dr. Iakobishvili chairs the Working Group on the Surveillance and Management of Cardio-Oncology Patients of Israel Ministry of Health Council on Management and Prevention of Heart and Vascular Diseases. Dr. Iakobishvili founded the first biennial International Cardio-Oncology Meeting in Israel. To this day, two meetings took place, both of which were highly attended and influential, attracting participants from more than 10 countries. The meetings raised the awareness of the importance of this field for the broader cardiology and oncology audiences. Dr. Iakobishvili is actively engaged in the organization of community heart failure clinics in the Tel Aviv district of Clalit Health Services which improves the process of evidence-based care delivery. He is a strong believer of patient and care-givers engagement in the care process to improve the outcomes. His main fields of scientific interest are: cardio-oncology, chronic heart failure, epidemiology of cardiotoxicity of anti-cancer therapy, prevention and treatment of cardiotoxicity, diabetes treatment in cardiac patients, cardiac biomarkers, cardiogenic shock, acute coronary syndromes and acute heart failure.

Roohi Ismail-Khan, MD, MSc

GCOS 2018 Co-Chair; Medical Oncologist and Co-Director, Cardio-Oncology Program, Moffitt Cancer Center and Research Institute, Tampa, FL, USA

founder

Dr. Roohi Ismail-Khan is an Associate Member at Moffitt Cancer Center in the Comprehensive Breast Program. She completed her Internal Medicine Residency at the University of South Florida and served as Chief Resident. She completed her Medical Oncology Fellowship at the H. Lee Moffitt Cancer Center as well as completed her MS in Clinical Research during her fellowship.  

Conference Topic: GCOS 2018 Welcome & Introduction

Conference Topic: Session 2 - Modern Treatments for Breast Cancer: From Anthracyclines to CD4/6 Inhibitors

Conference Topic: Opening Remarks and Day 1 Overview

 

Read More...

Her research interests include reducing or eliminating long-term effects of chemotherapy and to improve quality of life in breast cancer patients, particularly in metastatic breast cancer patients. Her clinical research is also focused upon identifying high risk patient cohorts and minimizing cardiovascular side effects in patients receiving cardiotoxic therapy. She serves as principal investigator on both investigator initiated and pharmaceutical sponsored clinical trials. She serves as the co-director of the USF/Moffitt Cardio-Oncology program. Dr. Ismail-Khan is also an active teacher and mentor for USF medical students, Internal Medical residents, and Medical Oncology Fellows.

Nikhil Khushalani, MD

Vice-Chair and Associate Member, Department of Cutaneous Oncology, Moffitt Cancer Center; Associate Professor, Morsani College of Medicine, University of South Florida, Tampa, FL, USA

founder

Dr. Nikhil Khushalani is the Vice-Chair and an Associate Member in the department of Cutaneous Oncology at the Moffitt Cancer Center, Tampa. FL, and holds a joint appointment as Associate Professor in the Morsani College of Medicine, University of South Florida.  He received his Bachelor of Medicine and Bachelor of Surgery (MBBS) degree (1995) at the T.N. Medical College, University of Bombay, India, followed by residency in Internal Medicine (1999) at the State University of New York, Buffalo. 

Conference Topic: Session 9 - The Rapidly Evolving Field of Immunotherapy to Treat Malignancy: From Checkpoint Inhibitors to CAR-T

Read More...

A three-year fellowship in Medical Oncology (2002) was completed at the Roswell Park Cancer Institute, Buffalo, NY.  Dr. Khushalani is an ABIM-certified in Internal Medicine and Medical Oncology. Prior to joining the Moffitt Cancer Center in August 2015, Dr. Khushalani was the Section Chief for Soft Tissue and Melanoma Medicine at the Roswell Park Cancer Institute in Buffalo, New York from 2010-15 and was a faculty member in the division of Medical Oncology from 2006-15. Before this, he worked as an attending physician in Oncology from 2002-2006 at the Veterans Affairs Medical Center in Buffalo. Dr. Khushalani is a clinical investigator and his research interests pertain to novel molecular therapeutics in melanoma and other skin cancers. Specifically he is interested in examining the role of anti-angiogenic agents in melanoma and also studying the pharmacoeconomic impact of the new agents now available in melanoma on the healthcare system. Dr. Khushalani has over 60 manuscripts and book chapters along with greater than 100 abstracts to his credit with presentations at national and international meetings. Dr. Khushalani was on the Melanoma Panel for the National Comprehensive Cancer Network (NCCN) from 2010 until 2015. Previously he has been a member of their panel for ‘Occult Primary Tumors’ and has also served on several ASCO committees (Career Development Committee, Cancer Education Committee, and Communications Committee) in the past. Dr. Khushalani is one of the founding members of the Midwest Melanoma Partnership in 2012, an alliance of several academic and community oncology practices with the common goal of enhancing the care of melanoma patients. At Roswell Park, he was the co-chair of the Institutional Review Board and was a member of the Medical Oncology Fellowship Committee and the Faculty Mentoring and Development Task Force amongst numerous other appointments. At Moffitt, he is a project leader of the Skin SPORE grant and is a member of the Scientific Review Committee. He was an editorial board member of the ‘World Journal of Clinical Oncology’, and has reviewed manuscripts for multiple journals, including the Journal of Clinical Oncology, Cancer Research, Lancet Oncology, Journal of the National Cancer Institute, Cancer, Cancer Investigation, and Oncology.

Bonnie Ky, MD, MSCE

Director, Penn Cardio-Oncology Center of Excellence; Director, Penn Center for Quantitative Echocardiography; Associate Professor of Medicine and Epidemiology, Division of Cardiology, University of Pennsylvania School of Medicine, Philadelphia, PA, USA

founder

Dr. Bonnie Ky, MD, MSCE is an Associate Professor of Medicine and Epidemiology at the University of Pennsylvania School of Medicine Division of Cardiology, a Senior Scholar in the Center for Clinical Epidemiology and Biostatistics, is the Director of the Penn Center for Quantitative Echocardiography, and Director of the Penn Cardio-oncology Center of Excellence.  

Chair: Session 6 - Young Investigator Competition

Conference Topic: Session 11 - Track 2: Year in Review - Top Basic/Translational Research Studies in Cardio-Oncology

Read More...

In this role, she leads a highly active NIH-funded translational research program aimed at identifying the underlying mechanisms and predictors of cancer therapy cardiotoxicity in many populations, including breast, renal cell, lung cancer and lymphoma. Specifically, her study objectives are to determine the role of mechanistic biomarkers and echocardiography-derived measures of myocardial mechanics in understanding and predicting incident cardiotoxicity and adverse cardiovascular outcomes with cancer treatment. She has specialized training in clinical epidemiology, the study of cardiovascular biomarkers, and the use of quantitative echocardiography as tools to understand cardiac remodeling and risk prediction.

Daniel J. Lenihan, MD, FACC

Professor of Medicine; Director, Cardio-Oncology Center of Excellence, Washington University Medical Center, St Louis, MO, USA. President, International Cardio-Oncology Society

founder

Dr. Lenihan, has been active in cardio-oncology and heart failure, for nearly 20 years. The main focus of these efforts have included hemodynamic assessments, angiogenic growth factor response, novel cardiac biomarkers as well as optimal methods to prevent or detect heart failure at the earliest stage possible in patients undergoing treatment for cancer.  

Keynote Debate: Session 10 - Are We Too Focused on the QT Interval with Oncology Treatments? Position: No

Read More...

His current projects include early phase clinical trials in cardio-oncology, heart failure and amyloidosis.  He is the PI of the PROTECT study looking at cardiac safety in patients undergoing proteasome inhibitor treatment for multiple myeloma and recently completed the PREDICT study, a large multicenter prospective study examining the role of cardiac biomarkers for the detection of cardiotoxicity and has been intimately involved in the latest treatment trials for cardiac amyloidosis.  He recently moved to Washington University in St Louis to enhance and expand their Cardio-Oncology Center of Excellence.  Dr Lenihan continues to enhance and foster collaboration among a host of colleagues both regionally, nationally, and throughout the world. He is the current president of the International Cardio-Oncology Society (ICOS), a professional association whose primary goal is to eliminate cardiac disease as a barrier to effective cancer therapy.

Jennifer Liu, MD, FACC, FASE

Director of CV Laboratories, Associate Professor of Clinical Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY, USA

founder

Jennifer Liu is a clinical cardiologist with an expertise in echocardiography. She directs the cardiovascular laboratories at Memorial Sloan Kettering Cancer Center. Her research and clinical interests focus  on the use of echo imaging modalities to enhance the diagnosis and management of cardiac disease related to cancer treatment.

Co-Chair: Session 11 - Track 1: Advanced Cardiovascular Imaging Techniques for Cardio-Oncology

Frederick Locke, MD

Vice Chair and Associate Member, Department of Blood and Marrow Transplant and Cellular Immunotherapy; Co-Leader, Immunology Research Program, Moffitt Cancer Center, Tampa, FL, USA

founder

Dr. Fred Locke is the Vice Chair and an Associate Member of the Department of Blood and Marrow Transplant and Cellular Immunotherapy, and the Co-Leader of the Moffitt Cancer Center Immunology Research Program. Dr. Locke is an oncologist and translational investigator dedicated to the development of cellular therapies for lymphoma and multiple myeloma.  

Co-Chair: Session 9 - Immunotherapy and Associated Cardiotoxicity

Read More...

He is a nationwide lead investigator for several multi-center studies treating aggressive lymphoma patients with anti-CD19 CAR T cells. Results from the ZUMA-1 trial were recently reported in the New England Journal of Medicine and supported FDA approval of Yescarta, the first FDA approved gene modified cellular therapy to treat lymphoma. Dr. Locke is the Research Director and Clinical Director for the Immune Cell Therapy program at Moffitt and also serves as Chair of both the Moffitt Cellular Therapy Advisory Committee and the Moffitt Immunotherapy Working Group.

Sagar Lonial, MD

Professor and Chair, Department of Hematology and Medical Oncology, Chief Medical Officer, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA, USA

founder

Sagar Lonial completed his medical degree at the University of Louisville School of Medicine in Kentucky. He completed his internship and residency at Baylor College of Medicine in Houston, Texas; served as Chief Medical Resident at the Ben Taub General Hospital and the Texas Heart Institute at St. Luke’s Hospital; and completed a fellowship in hematology/oncology at Emory University School of Medicine.  

Conference Topic: Session 2 - Cardiovascular Safety of Proteasome Inhibitors and Immunotherapy Drugs for the Treatment of Multiple Myeloma

Read More...

Board certified in hematology and medical oncology, Dr. Lonial is internationally recognized as a leading authority in multiple myeloma treatment and research. He is involved in numerous professional organizations, including the American Society of Clinical Oncology, the American Society of Hematology, and the American Society for Blood and Marrow Transplantation. He is Vice Chair of the Myeloma Committee in the Eastern Cooperative Oncology Group and Chair of the Steering Committee for the Multiple Myeloma Research Consortium. Additionally, he is on the board of directors for the International Myeloma Society and the scientific Advisory Board for the International Myeloma Foundation. He is also a member of the Discovery and Developmental Therapeutics Research Program at Winship Cancer Institute of Emory University. Dr. Lonial’s recent research has focused on combinations of novel agents as therapy for myeloma and lymphoma, and particularly on evaluating combinations that may result in synergistic inhibition of the PI3-K/Akt pathway. His lab has recently received funding from the Multiple Myeloma Research Foundation, the Lymphoma Research Foundation, and The Leukemia & Lymphoma Society. Dr. Lonial has authored over 200 peer-reviewed publications. He serves on the editorial board of the Journal of Clinical Oncology and Leukemia; is the myeloma editor for Clinical Lymphoma, Myeloma, and Leukemia; and is the hematologic malignancies section editor for the journal Cancer. In addition, he is an invited or ad hoc reviewer for several publications, including Blood, and Haematologica, Clinical Cancer Research, The New England Journal of Medicine, and others. Dr. Lonial’s research focuses on combination therapy in B-cell malignancies focusing on myeloma. He is a trained bone marrow transplant physician with an interest in molecular therapy for lymphoma and myeloma. His clinical interests include evaluating the combination of new molecular targeted agents for B-cell cancers, as well as methods to enhance immunity following allogeneic or autologous stem cell transplant. Dr. Lonial is a member of several local committees as well as a member of several committees for the American Society of Hematology. He is also involved in numerous professional organizations including the American Society of Clinical Oncology and the American Society for Blood and Marrow Transplantation. In addition, he serves on the editorial board of the American Journal of Clinical Oncology and as an invited or ad hoc reviewer for several publications, including Blood, Journal of Clinical Oncology, and Haematologica, Clinical Cancer Research, Leukemia, and others. Dr Lonial has authored or coauthored numerous publications and abstracts and has given several presentations, locally, nationally, and internationally.

Alexander Lyon, MA, BM, BCh, PhD, FRCP, FHFA

Senior Lecturer in Cardiology, Imperial College London; Consultant Cardiologist & Clinical Lead for Cardio-Oncology Service, Royal Brompton Hospital, London, United Kingdom. President, British Cardio-Oncology Society.

founder

Dr. Alexander Lyon is a Senior Lecturer in Cardiology at Imperial College London and a Consultant Cardiologist at the Royal Brompton Hospital. His clinical interests are in the field of heart failure, cardio-oncology including chemotherapy cardiomyopathy and the cardiovascular complications of modern cancer therapies, Takotsubo syndrome, and the development of novel therapeutics including gene therapy for chronic heart failure.  

Co-Chair: Session 9 - Immunotherapy and Associated Cardiotoxicity

Conference Topic: Session 12 - Developing a Cardio-Oncology Program in an Academic Environment

Read More...

Dr. Lyon is the clinical lead for the Cardio-Oncology service at the Royal Brompton Hospital since 2011, specialising in surveillance and cardioprotection from modern cancer drugs, risk stratification and treatment of all cardiac complications of cancer treatment. He is the current president of the British Cardio-Oncology Society (formerly the UK Cardio-Oncology Consortium) and the cardiology advisor to the charity Macmillan Cancer. Dr. Lyon was recently appointed chair of the European Society of Cardiology Heart Failure Association Cardio-Oncology Study Group and he is a co-author of their ESC Position Statement on Cardio-Oncology. He is a member of the International Cardio-Oncology Society and is co-chair of the 2017 ICOS-BCOS hosted Global Cardio-Oncology Summit in London.

Michael J. Mauro, MD

Leader, Myeloproliferative Neoplasms Program, Leukemia Service; Professor of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA

founder

Dr. Michael Mauro is a board-certified hematologist, professor, and leader of the Myeloproliferative Neoplasms Program, Leukemia Service, Memorial Sloan Kettering Cancer Center in New York City. After receiving his BS and MD from Dartmouth College and Dartmouth Medical School in New Hampshire, he completed both residency and fellowship training at the New York-Presbyterian Hospital/Weill Cornell Medical College in Manhattan.  

Conference Topic: Session 2 - Cardiotoxicities of Tyrosine Kinase Inhibitors to Treat CML and CLL: Heart Attacks, Strokes, and Atrial Fibrillation Oh My!

Read More...

Before joining Memorial Sloan Kettering, Dr. Mauro was on the faculty of Oregon Health and Sciences University for 13 years, where he directed the CML clinical trial program and was involved in the early development and sentinel clinical studies of ABL kinase inhibitors for CML. Dr. Mauro’s clinical expertise is in treating patients with chronic myeloid leukemia (CML) as well as other myeloproliferative disorders, including myelofibrosis, polycythemia, and thrombocytosis as well as less common conditions such as eosinophilic and mast cell disorders. He holds positions on the boards of the International CML Foundation, the MAX Foundation, and the Leukemia and Lymphoma Society.

Howard L. McLeod, PharmD

Medical Director, DeBartolo Family Personalized Medicine Institute; Chair, Department of Individualized Cancer Management; Senior Member, Division of Population Sciences, Moffitt Cancer Center and Research Institute, Tampa, FL, USA

founder

Dr Howard McLeod is Medical Director of the DeBartolo Family Personalized Medicine Institute at the Moffitt Cancer Center. He is chair of the Department of Individualized Cancer Medicine and a State of Florida Endowed Chair in Cancer Research. He is also a Senior Member of the Division of Population Sciences and Professor at the University of South Florida.     

Conference Topic: Session 11 - Track 2: Genomics and Personalized Medicine to Identify Those at Risk for Cardiotoxicity

Read More...

Dr McLeod is chair of the NHGRI eMERGE network external scientific panel and a recent member of the FDA committee on Clinical Pharmacology and the NIH Human Genome Advisory Council. Since 2002, Dr McLeod has been vice chair for Pharmacogenomics for the major NCI clinical trials group, overseeing the largest oncology pharmacogenomics portfolio in the world. Dr McLeod is also a 1000 talent scholar of China and a Professor at Central South University in Changsha, China. Howard has published over 530 peer reviewed papers on pharmacogenomics, applied therapeutics, or clinical pharmacology and continues to work to advance individualized medicine.

Chiara Melloni, MD, MHS, FACC

Associate Professor of Medicine, Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA

founder

Chiara Melloni, MD, MHS, FACC is an Associate Professor of Medicine at Duke Clinical Research Institute, Duke University Medical Center. She leads the Duke Cardio-Oncology working group and co-chaired the inaugural Duke Cardio-Oncology symposium in 2016. She is currently co-PI on an international randomized trial to assess the cardiovascular effects of Degarelix (GnRH receptor antagonist) vs leuprolide (GnRH receptor agonist) therapy in men with prostate cancer. 

Keynote Debate: Session 5 - Should Direct Oral Anticoagulants Be Utilized in Cancer Patients to Prevent Thrombosis? Position: Yes

Read More...

Her research interest is focused on the optimal cardiovascular treatment of patients with cardiovascular disease and concomitant cancer, with specific focus on anticoagulant treatment and thrombotic and bleeding risk in patients with atrial fibrillation and cancer. Dr. Melloni completed her cardiology clinical training (graduating magna cum laude) at the University of Bologna, Italy in 2004. Subsequently she continued her training as a research fellow at the Duke Clinical Research Institute (DCRI) where she pursued training in clinical research and completed the Clinical Research Training Program obtaining a Master of Health Sciences in Clinical Research at Duke University in 2007. Dr. Melloni has published more than 50 articles in peer-reviewed journal and has authored a chapter of the book “Cardio-Oncology: The Clinical Overlap of Cancer and Heart Disease”. She is on the editorial board of the European Heart Journal-Cardiovascular Pharmacotherapy and ad hoc reviewer for multiple high-tier cardiology journals including Journal of the American Medical Association-Cardiology, Journal of American Heart Association, European Heart Journal, and New England Journal of Medicine.

Javid Moslehi, MD

Director, Vanderbilt Cardio-Oncology Program, Assistant Professor of Medicine, Vanderbilt University School of Medicine, Nashville, TN, USA

founder

Dr. Moslehi is an Assistant Professor of Medicine and the Director of the Cardio-Oncology Program at Vanderbilt School of Medicine. He graduated from Johns Hopkins University and University of Connecticut School of Medicine. He then completed an internal medicine residency at Johns Hopkins Hospital.  

Co-Chair: Session 3 - Plenary Lecture: The Role of Social Media in Promoting the Field of Cardio-Oncology with Tweeting Workshop and Audience Participation

Conference Topic: Session 12 - Developing a formalized Cardio-Oncology Fellowship and Educational Curriculum

Read More...

Following the completion of clinical cardiology fellowship at the Brigham and Women's Hospital and Harvard Medical School, he started a basic science post-doctoral fellowship at the Dana-Farber Cancer Institute focusing on the role of angiogenesis (formation of new blood vessels) in heart disease. In 2009, he founded the Cardio-Oncology program at Brigham and Women's Hospital/Dana-Farber Cancer Institute and Harvard Medical School with a clinic and research program focused on the cardiovascular care for cancer patients and cancer survivors. In 2014, he joined Vanderbilt. Dr. Moslehi is an expert clinician on the management of cardiac complications associated with radiation and both novel and traditional chemotherapies. His clinic and research program is focused on the mechanisms of toxicities associated with novel targeted therapies and how this knowledge can be modulated to understand human cardiovascular biology.

Negar Mousavi, MD

Director, Cardio-Oncology Program, McGill University Health Centre, Montreal, QC, Canada

founder

Dr. Negar Mousavi is an assistant professor of medicine at McGill University. Her advanced training was in multi-modality cardiovascular imaging including echocardiography, cardiac MRI, cardiac CT and nuclear cardiology. She is the director of the Cardio-Oncology program at McGill University Health Center. Her research interest is in the utility of advanced imaging techniques for detection of subclinical cancer-therapy related micro- and macrovascular disease.

Co-Chair: Session 8 - Malignancies with a Direct Effect on the Heart

Paul Nathan, MD, MSc, FRCPC

Director, Aftercare Program and Staff Oncologist, Hospital for Sick Children, Professor of Pediatrics and Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada

founder

Dr. Paul Nathan is a pediatric Hematologist/Oncologist and Director of the AfterCare clinic in the Division of Pediatric Hematology/Oncology at the Hospital for Sick Children in Toronto. He is an Associate Professor of Pediatrics and Health Policy, Management and Evaluation at the University of Toronto, and an adjunct scientist at the Institute for Clinical Evaluative Sciences.   

Conference Topic: Session 4 - Unique Cardiovascular Issues Facing Paediatric Cancer Survivors

Read More...

His research and clinical practice is focused on long-term outcomes in survivors of childhood cancer including the cardiac complications of cancer therapy. He is the principal investigator on a team grant focused on developing innovative imaging, biomarker and genetic methods for predicting risk for cardiac dysfunction in this population. His research is funded by CIHR, the Canadian Cancer Society, and the Ontario Institute for Cancer Research, among others.

Tomas G. Neilan, MD, MPH, MRCPI

Associate Professor of Medicine, Harvard Medical School; Director, Cardio-oncology Program, Co-Director, Cardiac MR PET CT Program, Division of Cardiology, Massachusetts General Hospital, Boston, MA, USA

founder

Dr. Neilan is an Associate Professor of Medicine at Harvard Medical School, the Director of the Cardio-Oncology Program at Massachusetts General Hospital, the co-Director of the Cardiac MR PET CT Program, and the Associate Director of the MGH T32 Training Program in Cardiovascular Imaging. He completed his MD at University College Dublin Medical School.  

Conference Topic: Session 9 - Immunotherapy Associated with Cardiotoxicity: Pathophysiology, Detection and Treatment Strategies

Read More...

He completed his clinical training in Internal Medicine and Cardiology at the Mater Hospital in Dublin and at Massachusetts General Hospital. He also competed advanced training in Echocardiography at Massachusetts General Hospital, a Cardiac MRI fellowship at the Brigham and Women’s Hospital and a master of public health degree at the Harvard School of Public Health. Dr. Neilan has been awarded the “de Gunzburg Family Endowed Scholar in Cardiology”, The Locke Award for excellence in medical education and elected as a Senior Fellow to the Oliver Wendell Holmes Society at Harvard Medical School. His career has had two major focuses: 1) Understanding how we can improve the cardiovascular care of patients with cancer and 2) The use of advanced imaging to better understand and characterize cardiovascular disease.

Aarti A. Patel, MD

Director, Advanced Cardiovascular Imaging Fellowship, Assistant Professor of Medicine, Department of Cardiovascular Sciences, University of South Florida, Morsani College of Medicine, Tampa, FL, USA

founder

Dr. Patel is an Assistant Professor of Medicine at the University of South Florida (USF) with clinical appointments at Moffitt Cancer Center, James A. Haley Veterans’ Affairs Hospital and Tampa General Hospital. As a practicing cardiologist, her clinical expertise is in Advanced Cardiac Imaging, including echocardiography, cardiac magnetic resonance imaging and cardiac computed tomography. 

Conference Topic:  Session 11 - Track 1: Echocardiography in Cardio-Oncology: Strain, 3D Imaging and Diastology

Workshop Moderator: Session 11 - Track 1: Techniques in Imaging Workshop

Read More...

She earned her Bachelor of Science degree at University of Miami (UM) and her Medical Doctorate at Florida State University College of Medicine. After completing residency at UM she completed both general and imaging fellowships at USF, later joining as faculty. She has special interest in multimodality imaging in diagnosis of cardiovascular disease and medical education. Her research interests include cardiomyopathy in Friedreich’s Ataxia and valvular disease. She has authored papers in cardio-oncology pertaining to multimodality imaging and medical education. She currently serves as the Director of the Advanced Cardiac Imaging Fellowship Program at USF and is a member of the American College of Cardiology Academic Council.

Naveen Pemmaraju, MD

Associate Professor, Department of Leukemia, MD Anderson Cancer Center, Houston, TX, USA

founder

Naveen Pemmaraju, MD is Associate Professor in the Department of Leukemia at MD Anderson Cancer Center. After graduating with a degree in Cell and Molecular Biology from Tulane University (cum laude), he completed medical school at University of Arkansas for Medical Sciences in his home state of Arkansas. From there, he went on to complete Internal Medicine training in the Osler Medical Program at Johns Hopkins Hospital (Barker Firm). 

Plenary Lecture: Session 3 - The Role of Social Media in Promoting the Field of Cardio-Oncology with Tweeting Workshop and Audience Participation

Read More...

Dr Pemmaraju has lived in the Houston area since 2008, where he completed his Hematology and Oncology fellowship at MD Anderson Cancer Center, being appointed one of the chief fellows for his program, and then stayed on as clinical/research faculty since 2011 in the Department of Leukemia.   His clinical practice and research work has focused on improving outcomes and developing novel therapies & clinical trials for adolescents, young adults, and older adult patients with acute myeloid leukemia (AML), chronic myeloid leukemia (CML), myeloproliferative neoplasms (MPN), as well as blastic plasmacytoid dendritic cell neoplasm (BPDCN). Dr Pemmaraju serves as national/lead PI for several clinical trials in the areas of MPN and BPDCN and is recognized for his work in developing novel targeted therapies for patients in these fields. Dr Pemmaraju has authored or co-authored over 100 manuscripts in the peer-reviewed medical literature. He has presented his work at many national/international meetings as posters and oral presentations (including ASH, AACR, ASCO, EHA). Dr Pemmaraju has been a pioneer in the early stages of developing social media and its interface with hematology/oncology, specifically in the creation of Twitter hashtag communities, as he is the founder of #MPNSM and #BPDCN.

Javier Pinilla-Ibarz, MD, PhD

Senior Member, Head of the Lymphoma Section, Director of Immunotherapy, Department of Malignant Hematology, Moffitt Cancer Center; Professor of Oncologic Sciences, College of Medicine, University of South Florida, Tampa, FL, USA

founder

Javier Pinilla-Ibarz, MD, PhD, is a Senior Member, Head of the Lymphoma Section and Director of Immunotherapy in the Department of Malignant Hematology at the H. Lee Moffitt Cancer Center in Tampa, Florida. Dr. Pinilla-Ibarz is also a Professor in the Department of Oncologic Sciences, College of Medicine, University of South Florida, Tampa, Florida.   

Co-Chair: Session 2 - New and Emerging Issues in Cardiotoxicity

Read More...

Dr. Pinilla-Ibarz has been leading the chronic leukemia program at Moffitt since 2006; and its principal interests in the clinic are patients with myeloid and lymphoid chronic leukemia. In this regard, Dr. Pinilla-Ibarz has participated in multiple clinical trials involving tyrosine kinase inhibitors, some of them now approved. As Director of Immunotherapy for Malignant Hematology, he has been involved in developing new immunotherapeutic approaches in malignant hematology. He has participated in several clinical trials of peptide and cellular vaccines in different hematological disorders. His laboratory is interested in epigenetic immunoregulation in lymphoid and myeloid leukemias. Other research focuses are on the role of the bone marrow microenvironment in mediating resistance to TKIs and the interaction of TKIs with the immune system. Dr. Pinilla-Ibarz frequently presents his findings at annual meetings of the American Hematology Association and the American Society of Clinical Oncology and other national/international meetings. His work has been published in journals including Blood, Nature Immunology, Seminars of Hematology and Leukemia. He has also authored multiple book chapters. Dr. Pinilla-Ibarz received both his MD and PhD from the University of Zaragoza, School of Medicine, Spain. He completed his residency in medicine and a fellowship in Hematology at La Paz University Hospital in Madrid, Spain; and after he moved to the US, he also completed a residency in Internal Medicine at Cornell Medical Center and a fellowship in Hematology/Oncology at the Memorial Sloan Kettering Cancer Center in New York City.

Juan Carlos Plana, MD

Chief, Clinical Operations of Cardiology, Department of Medicine, Baylor College of Medicine; Director, Cardio-Oncology Centre; Co-Director, Center for Advanced Cardiac Imaging, Baylor St. Luke’s Medical Centre, Houston, TX, USA

founder

Dr. Juan Carlos Plana Gomez  is Chief of Clinical Operations of the Section of Cardiology, Department of Medicine at Baylor College of Medicine, Director of the Cardio-Oncology Center, and co-Director of the Center for Advanced Cardiac Imaging at Baylor St. Luke’s Medical Center. He is the Don W. Chapman Chair in Cardiology and tenured Associate Professor of Medicine. Dr. Plana is board certified in Cardiology and Echocardiography.

Co-Chair: Session 11 - Track 1: Advanced Cardiovascular Imaging Techniques for Cardio-Oncology

Read More...

Dr. Plana earned his medical degree from Pontificia Universidad Javeriana, Santafé de Bogotá (Colombia). His extensive training included internship, residency, chief resident year and fellowship in Cardiovascular disease and Cardiac Imaging (echocardiography and Nuclear Cardiology) at Baylor College of Medicine. Dr. Plana’s academic career started at the University of Texas MD Anderson Cancer Center where he served as Director of Cardiac Imaging and Medical Director of the Echocardiography laboratory. In 2010, he was recruited to Cleveland Clinic, where he opened as served as Co-Director of the Cardio-Oncology center. Dr. Plana's clinical and research interests include Cardio-Oncology, valvular heart disease, diseases of the aorta, and advanced cardiac imaging. The major focus of Dr. Plana’s clinical and scholarly interest is the development and application of novel echocardiographic techniques in the early detection of cardiac dysfunction caused by chemotherapeutic agents. His work has led to 38 reports published in the peer-reviewed literature, as well as 8 invited reviews and book chapters. He authored the Expert consensus for multi-modality Imaging evaluation of cardiovascular complications of radiotherapy in adults, and more recently chaired the Expert consensus for the multi-modality Imaging evaluation of adult patients during and after cancer therapy: a joint effort of the American Society of Echocardiography and the European Association of Cardiovascular Imaging. His national and international stature in the field of Cardio-Oncology and cardiac imaging is reflected by his 122 invited presentations at national and international conferences; his invited service to 5 journal editorial boards (including his current service to the International Board of the Journal of Cardiovascular Echocardiography); and his invited service to, and leadership of multiple committees of the American Society of Echocardiography (for which he currently serves on the Board of Directors) and other professional societies (representing the United States on the Echocardiography Section of the Inter-American Society of Cardiology) , as well as to the NIH (NCI/NHLBI) (member of the Expert Panel on Cardio-toxicity) and the FDA. In addition to his scholarly efforts, Dr. Plana has been a dedicated educator, having received major teaching awards from BCM (Excellence in Teaching Award, 2000), M.D. Anderson Cancer Center (Teacher of the Year Award, Section of Cardiology, U. Texas Health Science Center, 2007), and the Cleveland Clinic (Teacher of the Year Award, Department of Cardiovascular Medicine, 2011).

Natalee Roper, RN, BSN, CHPN

Clinical Nurse and Cardio-Oncology Program Nurse Coordinator, Moffitt Cancer Center, Tampa, FL, USA

founder

Natalee Roper is a clinical nurse at Moffitt Cancer Center and is the nurse coordinator for the Cardio-Oncology Program working to educate patients about their cardiovascular health during their cancer journey as well as helping to them to better navigate the health care system. Natalee earned her Bachelor of Science in Nursing at the University of South Florida and has national certification in Hospice and Palliative Care. 

Conference Topic: Session 12 - The Role of Nursing in Cardio-Oncology

Read More...

Prior to starting her career at Moffitt, she spent her early years working on the progressive care, and cardiac post anesthesia care units, where her passion for cardiac care was nurtured. She worked with patients, so they could recover after open heart surgery, lung surgery, and other cardiac procedures. She began her career at Moffitt in 2010, where she worked on the telemetry in-patient unit for 7 years, before she transitioned to the out-patient setting.

Kathryn J. Ruddy, MD, MPH

Consultant, Associate Professor of Oncology, Director of Cancer Survivorship, Department of Oncology, Mayo Clinic College of Medicine and Science, Rochester, MN, USA

founder

Dr. Ruddy is an Associate Professor of Oncology at Mayo Clinic. She directs the Cancer Survivorship Program for the Mayo Clinic Department of Oncology in Rochester, MN, and she co-leads the Symptom Control and Survivorship Cross-Disciplinary Group for the Mayo Clinic Cancer Center across all sites. She is a member of the National Comprehensive Cancer Network Survivorship Guideline Panel, and she currently serves as vice-chair of the Symptom Intervention Committee for the Alliance for Clinical Trials in Oncology.   

Conference Topic: Session 4 - Minimizing Cardiovascular Complications in Patients with High Cancer Risk Genetic Syndromes (BRCA, Li Fraumeni Syndrome)

Read More...

Dr. Ruddy cares for patients with breast cancer and is engaged in clinical research that is primarily focused on the toxicities of cancer treatment.

Kristen Sanfilippo, MD, MPHS

Assistant Professor, Department of Medicine, Division of Hematology, Washington University School of Medicine, St. Louis, MO, USA

founder

Kristen Sanfilippo, MD, MPHS, is an Assistant Professor of Medicine at Washington University in St. Louis. Her clinical and research interest include treatment and prevention of VTE in patients with cancer. She holds a dual appointment at Washington University in St. Louis as well as at the St. Louis John Cochran VA Medical center. In 2012, Dr. Sanfilippo completed a Master degree in health outcomes research and epidemiology (Master of Population Health Sciences).

Keynote Debate: Session 5 - Should Direct Oral Anticoagulants Be Utilized in Cancer Patients to Prevent Thrombosis? Position: No

Read More...

Her research interest is focused on the prediction and prevention of VTE in patients with cancer. She currently is awarded an individual K award to develop a risk model for VTE in patients with multiple myeloma. Dr. Sanfilippo completed her hematology/oncology training at Washington University St. Louis in 2013 having previously completed residency training at University of Pittsburgh Medical Center in 2010.  She graduated from University of Missouri-Columbia School of Medicine in 2007. In addition to her individual K awarded in 2017, she participated on an institution K12 award from 2011-2014 as well as the American Society of Hematology Clinical Research Training Institute (ASH CRTI) in 2012. 

Kenneth H. Shain, MD, PhD

Assistant Member, Departments of Malignant Hematology & Tumor Biology, Moffitt Cancer Center and Research Institute, Tampa, FL, USA

founder

Dr. Kenneth Shain is an Assistant Member at the H. Lee Moffitt Cancer Center and Research Institute (Moffitt), with a primary appointment in the Department of Malignant Hematology, and a secondary appointment in the Department of Tumor Biology. He also serves as the Scientific Director of the Moffitt Myeloma Working Group (MMWG) and as the Director of the ORIEN MM Disease Interest Group (DIG) at Moffitt.   

Co-Chair: Session 8 - Malignancies with a Direct Effect on the Heart

Read More...

As a clinician-scientist he investigates the pathobiology of multiple myeloma (MM) and mechanisms of therapy resistance, including intrinsic mechanisms of resistance and that mediated by bone marrow tumor microenvironment (TME), to identify novel targets and tools to improve the management of multiple myeloma (MM). On the clinical side he treats MM patients and directs MM clinical trials. Dr. Shain's research has three major focuses: (i) development and use of pharmacoproteomic tools to identify vulnerabilities of MM and to identify drivers of therapy resistance in the context of the TME; (ii) development and use of ex vivo tools informed by mathematical models for personalized management of MM; and (iii) development and use of tissue, molecular and clinical bio-repositories/databases centered around gene expression profiling, whole exome sequencing (WES) and RNA sequencing (RNAseq) of MM patient specimens, to identify predictive and prognostic molecular biomarkers. The ultimate objective of Dr. Shain's research program is to address the critical need to identify tractable vulnerabilities to inform the development of targeted therapeutics with biomarkers facilitating truly personalized management in MM.

Christine Simmons, MD

Medical Oncologist, BC Cancer Agency Vancouver; Clinical Associate Professor, Department of Medicine, University of British Columbia, Vancouver, BC, Canada

founder

Dr. Christine Simmons is a Medical Oncologist at the BCCA Vancouver and Clinical Associate Professor in the Department of Medicine at the University of British Columbia. She completed her residency training in Toronto, and completed a fellowship at Princess Margaret Hospital in Toronto. She also completed a Master’s in Clinical Epidemiology at University of Toronto. She is currently the Chair of Sarcoma Systemic Program for BCCA.   

Co-Chair: Session 7 - Plenary Lecture: Reconciling Guidelines, Recommendations and Consensus Statements to Provide Optimal Cardio-Oncology Care

Read More...

She is the former chair of the Locally Advanced Breast Cancer National Consensus group and still plays a key role in that organisation. Her academic interests span both teaching and research, and she has held several leadership roles in the Undergraduate Medical Program at UBC in the areas of clinical skills and oncology education. Her research interests are in the areas of health services research in breast cancer and sarcoma. She recently founded the Sarcoma Outcomes Unit at the BC Cancer Agency, and is Founder and Chair of the not‑for‑profit organisation, Women in Cancer.

Susannah Stanway, MBChB, MRCP, MD, MSc

Consultant in Medical Oncology, The Royal Marsden NHS Foundation Trust, London, United Kingdom

founder

Dr Susannah Stanway is a Consultant in Medical Oncology at The Royal Marsden NHS Foundation Trust. Having qualified from Bristol University in 1998, she obtained an MD thesis for her work on Steroid Sulphatase Inhibition in postmenopausal patients with Breast Cancer from Imperial College in 2009; her oncology training was undertaken at UCLH and The Royal Marsden NHS Foundation Trust.   

Co-Chair: Session 3 - Plenary Lecture: The Role of Social Media in Promoting the Field of Cardio-Oncology with Tweeting Workshop and Audience Participation

Read More...

She has been working at consultant level since 2012, both in the Acute Oncology Service at Croydon University Hospital and in the Royal Marsden NHS Foundation Trust’s Breast Unit. Along with actively recruiting patients to the large portfolio of research studies in the Breast Unit, her research interest is predominantly focused on Cancer Survivorship. This includes the area of cardio-oncology, in collaboration with amongst others, the Cardio-Oncology Group at the Royal Brompton Hospital and the London School of Hygiene and Tropical Medicine (where she co-supervises a PhD student); treatment-induced Hot Flushes (where she sits on the NCRI Symptom Management Working Group); sexual and psychological consequences of cancer and has completed an MSc thesis on Risk Stratification to Guide Follow up after Childhood Malignancy. She co-chairs the Royal Marsden NHS Foundation Trust’s Living With and Beyond Cancer Committee; sits on the Royal Marsden Partners Vanguard Survivorship pathway and has set up a pan-London multi-disciplinary survivorship research group; she leads the Living with and Beyond Cancer Module on the Institute of Cancer Research (ICR) MSc course; and has been actively involved with the Royal Marsden NHS Foundation Trust’s Young Women’s Breast Cancer service since its inception; Susie has an interest in cancer control in low-middle income countries and she sits on the editorial board of ASCO’s Journal of Global Oncology, leads a sub-module on Cancer in Low-Middle Income Countries on the ICR MSc course, actively contributes to oncology education of junior doctors in East Africa with the East African Development Bank-British Council-Royal College of Physicians group, and has led the steering group “Cancer Control in Low and Middle Income Countries” meeting held annually at the Royal Society of Medicine. In 2017 received an award from the Global Challenges Research Fund for a study of unmet need in women following breast cancer treatment in Ghana and Tanzania. She is currently co-leading a series of five papers for The Lancet Oncology about cancer control in small island developing states. She is also co-chair of the RM/ICR Cancer Control in Low- and Middle-Income Countries Collaborative Group focusing on research and education in low resource settings. She is immediate past president of the Oncology Section at the Royal Society of Medicine.

Jonathan Strosberg, MD

Section Head, Neuroendocrine Division, Associate Professor, Moffitt Cancer Center and Research Institute, Tampa, FL, USA

founder

Dr. Jonathan Strosberg is an associate professor at the H. Lee Moffitt Cancer Center, specializing in management of gastrointestinal and neuroendocrine malignancies. He is a graduate of Harvard University and Cornell University Medical College, and completed his residency and fellowship training programs at Georgetown University Hospital and H. Lee Moffitt Cancer Center. He leads the neuroendocrine tumor division at Moffitt and heads the gastrointestinal department research program. He also serves as chair of the scientific review committee.  

Conference Topic: Session 8 - Cardiovascular Issues Due to Carcinoid and Other Neuroendocrine Tumors

Read More...

Dr. Strosberg has published over one hundred articles on the diagnosis and management of neuroendocrine malignancies in the New England Journal of Medicine, Lancet, Journal of Clinical Oncology, Annals of Oncology, Annals of Surgery, Cancer, and other major journals, and has written twelve articles for UptoDate. He is a recipient of the National Cancer Institute’s Clinical Investigator Team Leadership Award. He serves on the board of directors of the North American Neuroendocrine Tumor Society (NANETS), on the neuroendocrine guidelines committee of the National Comprehensive Cancer Network (NCCN), and on the neuroendocrine task force of the National Cancer Institute (NCI) and the neuroendocrine staging committee of the American Joint Committee on Cancer (AJCC).

Sebastian Szmit, MD, PhD

Assistant Professor of Medicine; Cardiologist & Specialist of Internal Medicine, Centre of Postgraduate Medical Education, Otwock, Warsaw, Poland

founder

Sebastian Szmit graduated from the Military Medical Academy in Poland, worked as an internal medicine doctor in the Military Institute of Medicine (2003-2012) and the Medical University of Warsaw (2007-2012). From 2012, he is a Cardio-Oncology Consultant and Chief of the Laboratory of Cardio-Pulmonary Exercise Testing in the Department of Pulmonary Circulation and Thromboembolic Diseases, Centre of Postgraduate Medical Education at the European Health Centre in Otwock.  

Co-Chair: Session 4 - Cardiovascular Toxicity Prevention and Treatment in Special Populations

Read More...

Sebastian Szmit is the tutor of two PhD projects: (1)Comprehensive geriatric and cardio-oncological assessment as predictive and prognostic factors in selected cancer patients aged 65 years or older; (2) Prognostic value of selected cardiac echocardiographic parameters in patients receiving cardiotoxic anticancer therapy. Sebastian Szmit is the member of the Polish Cardiac Society & European Society of Cardiology (ESC). He was appointed the executive editor of the Task Force of National Consultants in Cardiology and Clinical Oncology, to develop the first two Polish documents of Recommendations of National Team of Cardiologic and Oncologic Supervision on cardiologic safety of patients with breast cancer (in 2010) and lung cancer (in 2012). He was invited as the reviewer for 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines. -Author and Lecturer of the Specialized Course entitled "Oncology in Cardiology" in Centre of Postgraduate Medical Education in Poland. -Editor-in-Chief of OnCOReview - the Official Journal of East European Branch of the International Cardio-Oncology Society. -Research Coordinator in Cardio-Oncology Section of the Polish Lymphoma Research Group. -Clinical Lead for Onco-Cardiology Team of the Polish National Oncology Network.

Dinesh Thavendiranathan, MD, MSc SM, FRCPC, FASE

Director, Ted Rogers Program in Cardiotoxicity Prevention, Toronto General Hospital, Associate Professor of Medicine; University of Toronto, Toronto, ON, Canada

founder

Dr. Paaladinesh Thavendiranathan MD, MSc SM, FRCPC, FASE is a cardiologist at the Toronto General Hospital, University of Toronto. He is an Associate Professor of Medicine and a Clinician Investigator.  His training was in advanced cardiovascular imaging and his current clinical practice involves work with cardiac MRI, CT, and echocardiography.  

Conference Topic: Session 11 - Track 1: The Role of CMR in the Evaluation and Management of the Cardio-Oncology Patient

Moderator: Session 11 - Track 1: Techniques in Imaging Workshop

Read More...

He is the Director of the Ted Rogers Program in Cardiotoxicity Prevention which focuses on cardiac toxicity from systemic therapies including cancer therapy. His research focus is in the use of advanced cardiac imaging techniques for detection and management of cardiac toxicity.

Carlo Gabriele Tocchetti, MD, PhD

Associate Professor of Medicine, Federico II University, Naples, Italy

founder

Prof. Carlo Gabriele Tocchetti got his MD in 1997, his Board in Cardiology in 2001 and his PhD in 2007 at Federico II University, Naples, Italy, and is currently Associate Professor of Medicine in the Department of Translational Medical Sciences, Federico II University, Naples, Italy since 2014, where he coordinates the Heart Failure outpatient unit, with a particular interest on HF due to antineoplastic therapies.

Co-Chair: Session 6 - Young Investigators Competition

Read More...

His cardio-oncologic interest developed in 2009 when he was a postdoctoral research fellow at Johns Hopkins University, Baltimore, MD, in the lab directed by Nazareno Paolocci, MD, PhD, and started collaborating with Kathy Gabrielson, PhD, dissecting the role of ErbB2 in the myocardium. These studies have been finally published on Cardiovasc Res, 2016. His previous studies and ongoing collaborations with Drs Kass and Paolocci in Baltimore have helped dissecting the cardiac contractile effects of HNO and the development of a novel HNO donor for treating human heart failure currently used in clinical trials. Back in Italy in 2010, Prof. Tocchetti established himself as a cardio-oncologic basic and clinical investigator, as witnessed by many publications on the topic as corresponding author. Prof. Tocchetti is also member of the Study Group on Cardio-Oncology of the Heart Failure Association of the ESC, and is Chair of the Working Group of Cardiotoxicity and Cardioprotection of the Italian Society of Cardiology (SIC). The main goal of his lab is to explore pathophysiologic mechanisms and therapeutic targets in cardiac dysfunction, with a particular interest on post-ischemic HF, genetic and inflammatory cardiomyopathies, Pulmonary Hypertension and RV dysfunction, and HF due to antineoplastic therapies, including novel anticancer immunotherapies and biologic drugs employed in inflammatory diseases.

Samuel A. Wickline, MD

Director of the University of South Florida Health Heart Institute, TGH Endowed Chair in Cardiovascular Medicine, Interim Director of the Department of Cardiovascular Sciences, Associate Dean for Cardiovascular Research, Professor of Cardiovascular Sciences, Professor of Molecular Physiology, Morsani School of Medicine, Tampa, FL, USA

founder

Samuel A. Wickline, M.D., Director of the USF Health Heart Institute, is the TGH Endowed Chair in Cardiovascular Medicine, Interim Director of the Department of Cardiovascular Sciences, Associate Dean for Cardiovascular Research, and Professor of Cardiovascular Sciences, and Professor of Molecular Physiology. He moved to USF in December 2016 from Washington University School of Medicine where he held academic positions as Professor Medicine, Physics, Biomedical Engineering, and Cell Biology and Physiology at Washington University.

Co-Chair: Session 11 - Track 2: Cardio-Oncology Research and Investigation

Read More...

In St Louis he was Director of the Cardiovascular Division at Jewish Hospital and subsequently Co-Director of the Cardiovascular Division at Barnes-Jewish Hospital. He was a founding member of the Washington University graduate program in Biomedical Engineering (the Institute for Biological and Medical Engineering), which subsequently evolved as the Department of Biomedical Engineering. He established the Washington University “Consortium for Translational Research in Advanced Imaging and Nanomedicine” (C-TRAIN) at the St Louis CORTEX Center devoted to diagnostic and therapeutic development of nanotechnology in concert with corporate and academic partners for broad-based clinical applications. He established one of the first clinical and research programs for Cardiac Magnetic Resonance Imaging in concert with corporate partner Philips Medical Systems and was a founding member of the International Society for Cardiovascular Magnetic Resonance. He has been an Established Investigator of the American Heart Association, a member of the American Society for Clinical Investigation, and recipient of a number of awards for teaching, entrepreneurship, and academics at Washington University. He has been funded continuously for 30+ years by the National Institutes of Health by numerous grants totaling more than $30 million. Dr. Wickline also is a founder of 4 biotech startup companies pursuing the development of personalized nanomedicines and medical diagnostic imaging devices. He also founded the St Louis Institute of Nanomedicine, a consortium of academic and commercial partners devoted to enhancing regional infrastructure for the translational advancement of nanotechnology in medicine. He is the author of over 300 research papers and holds more than 50 issued or filed U.S. patent applications. Numerous graduate students have undertaken their doctoral training in his laboratory in the fields of Cellular and Molecular Physiology, Computational Biology, Physics, and Biomedical Engineering.

Ronald Witteles, MD

Co-Director, Stanford Amyloid Center, Internal Medicine Residency Program Director, Associate Professor of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, CA, USA

founder

Ronald Witteles, M.D. (Associate Professor of Cardiovascular Medicine, Stanford University School of Medicine) is a graduate of The University of Chicago Pritzker School of Medicine, and completed his residency, chief residency, and fellowship training at Stanford University. He holds ABIM board certification in Internal Medicine, Cardiovascular Disease, and Advanced Heart Failure and Transplant Cardiology. 

Conference Topic: Session 8 - Amyloidosis: Challenges in Diagnosis and Management

 

Read More...

Dr. Witteles serves as Program Director for Stanford University’s Internal Medicine residency training program, and in that role he directly supervises >125 Internal Medicine residents and oversees all of the fellowship training programs in the Department of Medicine. He was a founder of and is Co-Director of the Stanford Amyloid Center, one of the nation’s leading centers for the treatment/research of amyloidosis. Dr. Witteles leads the Cardio-Oncology program at Stanford, and has published extensively in both the fields of Cardio-Oncology and amyloidosis.